KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$15.9 million.

  • Emergent BioSolutions' Cash from Financing Activities rose 9118.14% to -$15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 8805.17%. This contributed to the annual value of -$190.0 million for FY2024, which is 6453.24% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Cash from Financing Activities is -$15.9 million, which was up 9118.14% from -$6.4 million recorded in Q2 2025.
  • Emergent BioSolutions' Cash from Financing Activities' 5-year high stood at $353.1 million during Q4 2022, with a 5-year trough of -$486.9 million in Q2 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$10.5 million (2023), whereas its average is -$21.5 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Cash from Financing Activities crashed by 468260.87% in 2021, and later skyrocketed by 468600.0% in 2022.
  • Emergent BioSolutions' Cash from Financing Activities (Quarter) stood at -$110.0 million in 2021, then soared by 421.0% to $353.1 million in 2022, then crashed by 98.67% to $4.7 million in 2023, then crashed by 89.36% to $500000.0 in 2024, then crashed by 3280.0% to -$15.9 million in 2025.
  • Its Cash from Financing Activities was -$15.9 million in Q3 2025, compared to -$6.4 million in Q2 2025 and -$400000.0 in Q1 2025.